Facebook Twitter Linkedin Google Plus

Indatuximab Ravtansine: Good Tolerability and Signs of Efficacy in Phase I/IIa Clinical Trial

Indatuximab Ravtansine: Good Tolerability and Signs of Efficacy in Phase I/IIa Clinical Trial +

Indatuximab ravtansine, an antibody drug conjugate consisting of a monoclonal antibody and a highly potent cytotoxic maytansine derivative (DM4; N2′- Deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine), shows good tolerability and signs of efficacy in phase I/IIa clinical trial.

Read more

New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care

New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care +

A new cancer center model is helping meet the demand for better quality cancer care in community settings. Hybrid academic-community cancer centers began emerging and evolving at several sites in some southern and mid-Atlantic states during the last several years, and in February 2017 a number of their directors, and other key members of their respective institutions, gathered for a CME-sponsored full-day workshop in Miami to share experiences and best practices to advance the model.

Read more

News


View all

Editorial


View all


Latest Articles


View all

Expert Interview


View all

Must Read Articles


View all


Newsletter sign up

To subscribe to our weekly newsletter please send us your email address...

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.


Lonza

Go to top

ADC Review
is made possible by:

Stay in touch

Facebook Twitter Linkedin Google Plus

Skip to toolbar